Found: 18
Select item for more details and to access through your institution.
Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Micro sequential injection system as the interfacing device for process analytical applications.
- Published in:
- Biotechnology Progress, 2015, v. 31, n. 2, p. 607, doi. 10.1002/btpr.2055
- By:
- Publication type:
- Article
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 3, p. 434, doi. 10.1111/bjh.14698
- By:
- Publication type:
- Article
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 990, doi. 10.1007/s10637-022-01274-y
- By:
- Publication type:
- Article
Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies-results of a phase I dose-escalation study.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 6, p. 1487, doi. 10.1007/s10637-013-0010-4
- By:
- Publication type:
- Article
Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1265, doi. 10.1007/s10637-012-9910-y
- By:
- Publication type:
- Article
Poster 169: Prior Rotator Cuff Repair Is Not Associated with Worse Outcomes After Subsequent Superior Capsular Reconstruction: A Comparative Analysis.
- Published in:
- 2022
- By:
- Publication type:
- Abstract
Producing exposed cota-free embryos.
- Published in:
- Zygote, 1994, v. 2, n. 3, p. 221, doi. 10.1017/S096719940000201X
- By:
- Publication type:
- Article
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 2, p. 307, doi. 10.1007/s00280-012-2008-6
- By:
- Publication type:
- Article
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 3, p. 703, doi. 10.1007/s00280-010-1536-1
- By:
- Publication type:
- Article
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2010, v. 66, n. 4, p. 669, doi. 10.1007/s00280-009-1209-0
- By:
- Publication type:
- Article
Additional Practice-informing Adverse Event Patterns and Management in the KRYSTAL-1 Phase 2 Study of Adagrasib (MRTX849) in Patients With KRASG12C-mutated Non--Small Cell Lung Cancer.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2023, v. 14, n. 11, p. 350
- By:
- Publication type:
- Article
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 1, p. 105, doi. 10.1007/s11523-022-00931-9
- By:
- Publication type:
- Article
Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 2, p. 125, doi. 10.1007/s11523-022-00875-0
- By:
- Publication type:
- Article
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
- Published in:
- 2019
- By:
- Publication type:
- journal article